Disclosures: Guruprasad P. Aithal – Advisory Committees or Review Panels: Aegerion Pharmaceuticals, Abbott, UK, LtD, Falk Pharma; Consulting: Biogen Idec, OTSUKA PHARMACEUTICAL EUROPE LTD, Basilea Pharmaceutica; Speaking and Teaching: Lilly Indra Neil Guha – AP24534 solubility dmso Grant/Research Support: Pfizer, Conatus The following people have nothing to disclose: David J. Harman, Emilie A. Wilkes, Martin W. James, Stephen D. Ryder Purpose of the study: To measure the disparities in access to liver transplantation across UNOS region 1 using Geographic Information Systems (GIS) software. Methods:

Based on OPTN data, the number of transplant registrations (candidates) and transplants by zip code in November 2012 was obtained. ZIP code listing rate was calculated as the number of candidates performed divided by the ZIP code population. Transplant listing rates by zip code were mapped using ArcGIS software. A choropleth (color-coded) map was generated to display the geographic distribution of 2012 listing rates. The Spatial Scan Statistic (SatScan software) was used to identify geographic areas (clusters) with rates significantly higher or lower than the rest of the region. Spatial

regression analysis was Talazoparib in vitro performed to identify geographic and demographic factors in transplant listing rates. Factors tested included distance from the nearest transplant center, city over 50, 000 and population density. Results: A map of UNOS Region 1 transplant listing rates by zip code is shown in Figure 1 below. The map shows disparities in organ access to organ allocation across the region. SPTLC1 Distance from the nearest transplant facility was the only significant factor in transplant listing rates identified by

spatial regression. More importantly, SatScan cluster analysis identified areas with significantly high (red outlines) or low listing rates (purple outlines) that were not solely a function of distance to the transplant center. Conclusion: GIS represents a new approach to evaluat ing access to liver transplantation within a region, which can be used to guide efforts in alleviating disparities. Disclosures: The following people have nothing to disclose: Rony Ghaoui, Jane Garb Background and Aims: The addition of telaprevir to pegylatedinterferon and ribavirin has improved sustained virologic response (SVR) rates for genotype 1 HCV, but has also increased adverse events (AEs) and costs. We estimated the total management cost of triple therapy in a real-world setting. Methods: Pre-treatment, on-treatment, and post-treatment costs were calculated using 2010 US estimates from Medicare, Agency for Healthcare Research and Quality(AHRQ, ), and Red Book WAC, adjusting for inflation. Resource utilization was based on standard practices and data on 134 patients who initiated telaprevir use at Mount Sinai Medical Center (5/201112/2011).